Assort Health Raises $120M Series C at $1.2B Valuation

Assort Health, a startup building AI agents that handle the phone calls and paperwork around patient care, raised a $120 million Series C on June 24, the company said. The round was led by Menlo Ventures and values the company at $1.2 billion, vaulting it into unicorn territory barely two years after launch and bringing its total funding past $222 million.

The pitch is narrow but deep: rather than a general chatbot, Assort sells AI agents tuned to the specific journey a patient takes through a clinic or hospital — scheduling, intake, referrals, document processing, medication refills, lab requests, payments and copilots that sit alongside front-desk staff. The company says its agents have now handled more than 190 million patient interactions, drawing on roughly 62,000 care protocols and 1.6 million decision pathways it has encoded to keep the automation inside clinical and administrative guardrails.

Demand has tracked the wider staffing crunch in U.S. healthcare, where front-office and call-center roles are chronically understaffed and patients routinely wait on hold to book an appointment. Assort says revenue grew roughly 20x over the past 15 months, a trajectory that drew a deep investor syndicate alongside Menlo: Lightspeed Venture Partners, Felicis, First Round Capital, Chemistry, Tau Ventures, Quiet Capital and former NFL quarterback Joe Montana's fund.

The deal is the latest sign that vertical AI agents — software aimed at one regulated industry rather than the whole economy — are where a lot of this cycle's revenue and valuation is concentrating. Healthcare is a particularly attractive target because the work is high-volume, rule-bound and expensive to staff, but it is also unforgiving: a wrong medication refill or a mishandled referral carries real clinical risk, which is why Assort leans on protocol libraries and human review rather than letting a model improvise.